Australian Stock Market Hits Record High, Small Caps Climb Ahead

Strategic Insights -

The Australian stock market continued its upward momentum, breaking records with the S&P/ASX 200 closing above 8,800 for the first time, as the Small Ordinaries Index (XSO) outperformed with a 1.46% gain. Despite weaker leads from the US, the market shrugged off global concerns, driven by strong demand for precious metals stocks, particularly silver, amid rising gold and silver prices. Most sectors saw solid gains, including Resources, Energy, and Technology, with Thursday off to a relatively quiet start for small caps as the Diggers & Dealers Mining Forum wraps up in Kalgoorlie, WA.

Key Takeaways:

  • The Australian stock market reached a record high, with the S&P/ASX 200 closing above 8,800 for the first time.
  • The Small Ordinaries Index (XSO) outperformed, rising 1.46% against the broader index's 0.84% gain.
  • Strong demand for precious metals stocks, particularly silver, amid rising gold and silver prices bolstered the market.
  • Most sectors, including Resources, Energy, and Technology, saw solid gains.
  • Tryptamine Therapeutics Ltd progresses a world-first clinical trial for Binge Eating Disorder using its TRP-8803 (IV-infused psilocin).
  • Nova Minerals Ltd reported breakthrough results in antimony ore sorting tests from its Styx antimony prospect at the Estelle Project in Alaska.

Statistics:

  • The S&P/ASX 200 closed above 8,800 for the first time.
  • The Small Ordinaries Index (XSO) rose 1.46%.
  • The broader index (S&P/ASX 200) rose 0.84%.
  • 132% upgrade to produce a high-grade antimony trisulfide concentrate was demonstrated in ore sorting tests by Nova Minerals Ltd.
  • Tryptamine Therapeutics Ltd's TRP-8803 (IV-infused psilocin) is being tested in a world-first clinical trial for Binge Eating Disorder.

Sources:

  • Bloomberg
  • Financial Times
  • Reuters